Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Palleon Pharmaceuticals Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution is decentralized, with 3 distinct examiners and 3 distinct art units involved. This distribution indicates that each of the company's active patent matters is being handled by a different official in a different technical division, suggesting a diverse range of pharmaceutical innovations. The presence of 3 distinct art units reflects the varied nature of the company's biotechnological research.
The busiest examiner, GODDARD, LAURA B, is assigned 1 busiest examiner pending action. Because the total number of pending office actions is 3, this examiner's workload represents a portion of the active cases. Practitioners must navigate the distinct procedural styles of 3 distinct examiners, as no individual official dominates the current portfolio activity. The lack of overlap between the examiners and art units means that success in an application may not provide a roadmap for the other pending matters. Understanding the specific tendencies of GODDARD, LAURA B is essential for managing 1 busiest examiner pending action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 50.8% | +13.6% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.3% | +43.3% |
| BORGEEST, CHRISTINA M | 1 | 55.7% | +21.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624121 | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | BORGEEST, CHRISTINA M | 51d overdue |
| 17624123 | RECOMBINANT SIALIDASES AND METHODS OF USING THE SAME | WEHBE, ANNE MARIE SABRINA | 43d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17624121 | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | BORGEEST, CHRISTINA M | 51d overdue |
| 17624123 | RECOMBINANT SIALIDASES AND METHODS OF USING THE SAME | WEHBE, ANNE MARIE SABRINA | 43d overdue |
| 18003234 | RECOMBINANT SIALIDASES WITH REDUCED PROTEASE SENSITIVITY, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1634 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18003234 | RECOMBINANT SIALIDASES WITH REDUCED PROTEASE SENSITIVITY, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | GODDARD, LAURA B | 1642 | §102§112DP | Non-Final OA | — | Pending | Dec 23, 2022 |
| 17624123 | RECOMBINANT SIALIDASES AND METHODS OF USING THE SAME | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112 | Final Rejection | 43d overdue | Pending | Dec 30, 2021 |
| 17624121 | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS, AND METHODS OF USING THE SAME | BORGEEST, CHRISTINA M | 1675 | §102§112 | Non-Final OA | 51d overdue | Pending | Dec 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPalleon Pharmaceuticals Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Laura B Goddard has the most, with 1 of Palleon Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
